The research proposed here is in the area of cancer predisposition genetics, and its focus is on the moderate- risk cancer susceptibility genes (ATM, CHEK2, etc.) in the biochemical pathway responsible for DNA double strand break homologous recombination repair (HRR). Most of the genes in the HRR pathway are breast cancer susceptibility genes, with several also being ovarian cancer susceptibility genes and/or pancreatic cancer susceptibility genes. In the first funding cycle, we discovered that the majority of pathogenic alleles in the moderate-risk HRR genes are individually rare missense substitutions (rather than the individually rare protein truncating variants that dominate the mutation spectrum of BRCA1 and BRCA2). From a clinical cancer genetics and patient counseling point of view, this observation creates a serious problem: the clinical testing labs typically report these rare missense substitutions as Variants of Unclear Significance (VUS). Because the VUS are not used for patient counseling, this means that the majority of the bona fide genetic risk detectable in the moderate-risk HRR genes by the panel tests is not used for patient counseling and risk management! Over the last 12 years, we played a central role in development of methods for clinical classification of VUS in BRCA1 and BRCA2, and are currently developing corresponding methods for the colorectal (and other cancer) susceptibility genes MLH1, MSH2, PMS2, and MSH6. Here, we hypothesize that combining improved computational methods for rare missense substitution evaluation with comprehensive high-throughput functional assays will dramatically accelerate the process of evaluation and classification of clinically observed VUS. Thus the first Aim of the project focuses on confirming and then improving the accuracy of computational methods for evaluation of rare missense substitution.
The second Aim i s directed towards development of medium-to-high throughput assays of missense substitution functionality. In terms of genes, we will begin these studies with the RING domain of BRCA1 (which lacks a properly calibrated functional assay), and then progress to ATM and then CHEK2. In the third Aim, we re-calibrate the outputs from the computational methods of Aim 1 and the functional assays of Aim 2 into probabilities (or odds) in favor of pathogenicity, the key variables required for clinical-quality classification of sequence variants observed in people. We then combine these data to obtain posterior probabilities in favor of pathogenicity and pass those posterior probabilities through a well-recognized categorical classifier (the IARC standards) to generate classification recommendations for clinicians and patients. Progress across the three Aims of this study will dramatically accelerate variant classification while simultaneously improving the sensitivity and precision of the clinical testing process.
Inherited mutations in genes that normally help repair double strand breaks in DNA can increase people's risk of certain cancers, particularly breast, ovarian, and pancreatic cancers. Over the last five years we have dramatically increased our knowledge about which of these genes are involved in inherited cancer risk, but have not yet determined how to use the new information to prevent and early detect cancer in the people who have inherited these mutations. This study is designed to dramatically improve our ability to recognize the mutations in a broad population of patients and determine how much mutations in particular genes increase breast cancer risk so that the information can be used to prevent and/or enable early detection of these malignancies.
|Drost, Mark; Tiersma, Yvonne; Thompson, Bryony A et al. (2018) A functional assay-based procedure to classify mismatch repair gene variants in Lynch syndrome. Genet Med :|
|Fortuno, Cristina; James, Paul A; Young, Erin L et al. (2018) Improved, ACMG-compliant, in silico prediction of pathogenicity for missense substitutions encoded by TP53 variants. Hum Mutat 39:1061-1069|
|Tavtigian, Sean V; Greenblatt, Marc S; Harrison, Steven M et al. (2018) Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med 20:1054-1060|
|Young, E L; Feng, B J; Stark, A W et al. (2016) Multigene testing of moderate-risk genes: be mindful of the missense. J Med Genet 53:366-76|
|Easton, Douglas F; Lesueur, Fabienne; Decker, Brennan et al. (2016) No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J Med Genet 53:298-309|
|Park, Daniel J; Tao, Kayoko; Le Calvez-Kelm, Florence et al. (2014) Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers. Cancer Discov 4:804-15|
|Tavtigian, Sean V; Chenevix-Trench, Georgia (2014) Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. Biomark Med 8:589-603|
|Damiola, Francesca; Pertesi, Maroulio; Oliver, Javier et al. (2014) Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Res 16:R58|
|Le Calvez-Kelm, Florence; Oliver, Javier; Damiola, Francesca et al. (2012) RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study. PLoS One 7:e52374|
|Park, D J; Lesueur, F; Nguyen-Dumont, T et al. (2012) Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 90:734-9|
Showing the most recent 10 out of 17 publications